

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY  
PATENT APPLICATION  
TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	29248/21
First Inventor	Erik Buntinx
Title	METHOD OF TREATING NEURODEGENERATIVE DISEASES. ....
Express Mail Label No.	EL 996377277 US

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

## ADDRESS TO:

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

1. ☐ Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.  
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 44]  
(preferred arrangement set forth below)  
- Descriptive title of the invention  
- Cross Reference to Related Applications  
- Statement Regarding Fed sponsored R & D  
- Reference to sequence listing, a table,  
or a computer program listing appendix.  
- Background of the Invention  
- Brief Summary of the Invention  
- Brief Description of the Drawings (if filed)  
- Detailed Description  
- Claim(s)  
- Abstract of the Disclosure
4. ☐ Drawing(s) (35 U.S.C. 113) [Total Sheets \_\_\_\_\_]
5. Oath or Declaration [Total Sheets \_\_\_\_\_]  
a. ☐ Newly executed (original or copy)  
b. ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 18 completed)  
i. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s)  
name in the prior application, see 37 CFR  
1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or  
Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)  
a. ☐ Computer Readable Form (CRF)  
b. Specification Sequence Listing on:  
i. ☐ CD-ROM or CD-R (2 copies); or  
ii. ☐ Paper  
c. ☐ Statements verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement ☐ Power of  
(when there is an assignee) Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure ☐ Copies of IDS  
Statement (IDS)/PTO-1449 Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122  
(b)(2)(B)(i). Applicant must attach form PTO/SB/35  
or its equivalent.
17. ☒ Other: .....Cover Letter.....

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No.: 10/752,423

Prior application information:


Examiner \_\_\_\_\_

Art Unit: \_\_\_\_\_

For CONTINUATION OF DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 19. CORRESPONDENCE ADDRESS

☐ Customer Number: \_\_\_\_\_ OR ☒ Correspondence address below

Name	Alan D. Miller				
Address	AMSTER, ROTHSTEIN & EBENSTEIN LLP				
	90 Park Avenue				
City	New York	State	New York	Zip Code	10016
Country	USA	Telephone	(212) 336-8000	Fax	(212) 336-8001
Name (Print/Type)	Alan D. Miller		Registration No. (Attorney/Agent)	42,889	
Signature			Date	March 18, 2004	

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



15392 U.S. PTO

# AMSTER ROTHSTEIN & EBENSTEIN LLP

Intellectual Property Law

90 Park Avenue  
New York NY 10016

Main 212 336 8000

Fax 212 336 8001

Web www.arelaw.com

## Partners

Morton Amster  
Jesse Rothstein (1934 - 2003)  
Daniel Ebenstein  
Philip H. Gottfried  
Michael J. Berger  
Neil M. Zipkin  
Anthony F. Lo Cicero  
Kenneth P. George  
Abraham Kasdan, Ph.D.  
Ira E. Silfin  
Chester Rothstein  
Craig J. Arnold  
Kenneth M. Bernstein

## Senior Counsel

Charles R. Macedo  
Mark J. Rosenberg  
Nancy M. Dodderidge

## Of Counsel

Jerry D. Dainow

## Associates

Neal L. Rosenberg  
Patrick Boland\*  
Trebzor Lloyd  
Joseph M. Casino  
John S. Economou

Michael V. Solomita

Holly Pekowsky  
Michael P. Kenney  
Marion P. Metelski  
Max Vern  
Dana R. Metes  
Karl J. Kolbinger  
Brian A. Comack  
Richard S. Mandaro  
Marc J. Jason  
Elie H. Gendloff, Ph.D.  
David Mitnick  
Charles W. Rath  
David A. Boag

Karen J. Bernstein

Matthieu Hausig  
Jung S. Hahn  
Reiko Kaji  
Alan D. Miller, Ph.D.  
Hsin-Hsin (Ginger) Liu  
John A. Lepore\*  
Norajean McCaffrey

\*Not admitted in New York

March 18, 2004

Alan D. Miller

Direct 212 336 8094

E-mail amiller@arelaw.com

Via Express Mail

Mail Stop Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

"Express Mail" mailing label no.	EL 996377277 US
Date of Deposit:	March 18, 2004
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Name:	Alan D. Miller
Signature:	

Re: New U.S. Patent Application, Continuation-in-Part of  
U.S. Patent Application No. 10/752,423, Continuation-  
in-Part of U.S. Patent Application No. 10/725,965  
Title: METHOD OF TREATING NEURODEGENERATIVE  
DISEASES USING D4 AND 5-HT2A ANTAGONISTS,  
INVERSE AGONISTS OR PARTIAL AGONISTS

Inventor: Erik Buntinx

Our File: 29248/21

Dear Sir:

Enclosed please find a Continuation-in-Part application in the name of Erik Buntinx, entitled METHOD OF TREATING NEURODEGENERATIVE DISEASES USING D4 AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS OR PARTIAL AGONISTS, including the following:

1. a Utility Patent Application Transmittal sheet (Form PTO/SB/05);
2. a complete utility application, including specification (36 pages); claims (7 pages); abstract (1 page); and
3. a return receipt postcard.

This application is a Continuation-in-Part Application of U.S. Patent Application No. 10/752,423 filed January 6, 2004, which is a Continuation-in-Part of U.S. Application No. 10/725,965 filed December 2, 2003.

March 18, 2004


Please acknowledge receipt of the enclosed papers by stamping the enclosed postcard and returning the same to us.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicant  
90 Park Avenue  
New York, New York 10016  
(212) 336-8000

Dated: March 18, 2004  
New York, New York

By



Alan D. Miller, Reg. No. 42,889